Despite chemotherapy and novel androgen-receptor signalling inhibitors (ARSi) have been approved during the last decades, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with poor clinical outcomes. Several studies found that germline or acquired DNA damage repair (DDR) defects affect a high percentage of mCRPC...
-
2020 (v1)PublicationUploaded on: April 14, 2023
-
2020 (v1)Publication
Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastatic renal cell cancer patients not enrolled into clinical trials.
Uploaded on: April 14, 2023 -
2018 (v1)Publication
The multidisciplinary management of oncologic patients is identified as the bottom line element of quality in tumor care.
Uploaded on: April 14, 2023